Table 4.
Group differences in the association between the DRN and heteroreceptor 5-HT1A BPND
| Region | Functional ROI peak voxel |
|||||
|---|---|---|---|---|---|---|
| Patients after versus before SSRI |
Patients after SSRI versus healthy controls |
|||||
| MNI (mm) | t value | Z value | MNI (mm) | t value | Z value | |
| Amygdala | ||||||
| Right | 12, 0, −20 | 4.98*** | 2.78**# | 16, 0, −20 | 5.78***# | 3.38***# |
| Left | −16, −2, −22 | 2.76** | 2.62**# | −18, −2, −22 | 3.01** | 2.61**# |
| Hippocampus | ||||||
| Right | 18, −16, −14 | 4.39*** | 2.2* | 18, −14, −14 | 6.45***# | 3.9***# |
| Left | −18, −24, −16 | 3.82*** | 2.04* | −18, −24, −16 | 4.46*** | 3.09**# |
ROIs were defined functionally as clusters where patients showed significantly steeper regression slopes after treatment** (see Fig. 2). t and Z values of these functional ROIs represent peak differences in the regression slope β and correlation coefficient R, respectively, when comparing patients before and after escitalopram medication (see Fig. 2a,b) as well as between treated patients and healthy subjects (see Fig. 2c,d).
*p < 0.05; **p < 0.01; ***p < 0.001; #withstanding correction for multiple comparisons (FDR and Bonferroni-Holm for t and Z values, respectively).